{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:22:45Z","timestamp":1770751365990,"version":"3.50.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T00:00:00Z","timestamp":1500854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T00:00:00Z","timestamp":1500854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s40263-017-0458-4","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T09:04:35Z","timestamp":1500887075000},"page":"809-819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial"],"prefix":"10.1007","volume":"31","author":[{"given":"Paola","family":"Bozzatello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Uscinska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6555-8000","authenticated-orcid":false,"given":"Silvio","family":"Bellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,24]]},"reference":[{"key":"458_CR1","unstructured":"National Collaborating Centre for Mental Health. Borderline personality disorder: the NICE guideline on treatment and management. National Clinical Practice Guideline. British Psychological Society & Royal College of Psychiatrists. 2009; 78. http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG78FullGuideline.pdf."},{"key":"458_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1176\/appi.ajp.158.1.1","volume":"158","author":"American Psychiatric Association","year":"2001","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry. 2001;158:1\u201352.","journal-title":"Am J Psychiatry."},{"key":"458_CR3","volume-title":"Guideline watch: practice guideline for the treatment of patients with borderline personality disorder","author":"JM Oldham","year":"2005","unstructured":"Oldham JM. Guideline watch: practice guideline for the treatment of patients with borderline personality disorder. Arlington: American Psychiatric Association; 2005."},{"key":"458_CR4","first-page":"1667","volume":"176","author":"S Benjaminsen","year":"2014","unstructured":"Benjaminsen S. Pharmacotherapy effectiveness for some symptoms of borderline personality disorder. Ugeskr Laeger. 2014;176:1667\u201371.","journal-title":"Ugeskr Laeger."},{"key":"458_CR5","doi-asserted-by":"publisher","first-page":"CD005653","DOI":"10.1002\/14651858.CD005653.pub2","volume":"16","author":"J Stoffers","year":"2010","unstructured":"Stoffers J, V\u00f6llm BA, R\u00fccker G. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010;16:CD005653. doi:10.1002\/14651858.CD005653.pub2.","journal-title":"Cochrane Database Syst Rev."},{"key":"458_CR6","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s11920-014-0534-0","volume":"17","author":"JM Stoffers","year":"2015","unstructured":"Stoffers JM, Lieb K. Pharmacotherapy for borderline personality disorder\u2013current evidence and recent trends. Curr Psychiatry Rep. 2015;17:778\u201391. doi:10.1007\/s11920-014-0534-0 \n                           PMID: 25413640.","journal-title":"Curr Psychiatry Rep."},{"key":"458_CR7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/JCP.0b013e3182217a69","volume":"31","author":"TJ Ingenhoven","year":"2011","unstructured":"Ingenhoven TJ, Duivenvoorden HJ. Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains. J Clin Psychopharmacol. 2011;31:489\u201396. doi:10.1097\/JCP.0b013e3182217a69.","journal-title":"J Clin Psychopharmacol."},{"key":"458_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1521\/pedi.2009.23.2.156","volume":"23","author":"D Mercer","year":"2009","unstructured":"Mercer D, Douglass AB, Links PS. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. J Pers Disord. 2009;23:156\u201374. doi:10.1521\/pedi.2009.23.2.156.","journal-title":"J Pers Disord."},{"key":"458_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/01.yic.0000224784.90911.66","volume":"21","author":"M Nos\u00e8","year":"2006","unstructured":"Nos\u00e8 M, Cipriani A, Biancosino B. Efficacy on pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2006;21:345\u201353. doi:10.1097\/01.yic.0000224784.90911.66.","journal-title":"Int Clin Psychopharmacol."},{"key":"458_CR10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.4088\/JCP.v62n0413d","volume":"62","author":"DW Hough","year":"2001","unstructured":"Hough DW. Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder. J Clin Psychiatry. 2001;62:296\u20137.","journal-title":"J Clin Psychiatry."},{"key":"458_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.genhosppsych.2006.10.012","volume":"29","author":"C Damsa","year":"2007","unstructured":"Damsa C, Adam E, De Gregorio F. Intramuscular olanzapine in patients with borderline personality disorder: an observational study in an emergency room. Gen Hosp Psychiatry J. 2007;29:51\u20133. doi:10.1016\/j.genhosppsych.2006.10.012.","journal-title":"Gen Hosp Psychiatry J."},{"key":"458_CR12","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/S0006-3223(99)00128-6","volume":"46","author":"SC Schulz","year":"1999","unstructured":"Schulz SC, Camlin KL, Berry SA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry. 1999;46:1429\u201335. doi:10.1016\/S0006-3223(99)00128-6.","journal-title":"Biol Psychiatry."},{"key":"458_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4088\/JCP.v65n0118","volume":"65","author":"MP Bogenschutz","year":"2004","unstructured":"Bogenschutz MP, George Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104\u20139.","journal-title":"J Clin Psychiatry."},{"key":"458_CR14","first-page":"544","volume":"22","author":"M Jariani","year":"2010","unstructured":"Jariani M, Saaki M, Nazari H. The effect of olanzapine and sertraline on personality disorder in patients with methadone maintenance therapy. Psychiatr Danub. 2010;22:544\u20137.","journal-title":"Psychiatr Danub."},{"key":"458_CR15","doi-asserted-by":"publisher","first-page":"999","DOI":"10.4088\/JCP.v69n0617","volume":"69","author":"MM Linehan","year":"2008","unstructured":"Linehan MM, McDavid JD, Brown MZ. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69:999\u20131005. doi:10.1080\/105504999305686.","journal-title":"J Clin Psychiatry."},{"key":"458_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1055\/s-2006-941489","volume":"39","author":"JC Pascual","year":"2006","unstructured":"Pascual JC, Madre M, Soler J. Injectable atypical antipsychotics for agitation in borderline personality disorder. Pharmacopsychiatry. 2006;39:117\u20138. doi:10.1055\/s-2006-941489 \n                           PMID: 16721704.","journal-title":"Pharmacopsychiatry."},{"key":"458_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/JCP.0b013e3181c826ff","volume":"30","author":"SS Shafti","year":"2010","unstructured":"Shafti SS, Shahveisi B. Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial. J Clin Psychopharmacol. 2010;30:44\u20137. doi:10.1097\/JCP.0b013e3181c826ff.","journal-title":"J Clin Psychopharmacol."},{"key":"458_CR18","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1176\/appi.ajp.162.6.1221","volume":"162","author":"J Soler","year":"2005","unstructured":"Soler J, Pascual JC, Campins J. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162:1221\u20134. doi:10.1176\/appi.ajp.162.6.1221.","journal-title":"Am J Psychiatry."},{"key":"458_CR19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4088\/JCP.v62n1103","volume":"62","author":"MC Zanarini","year":"2001","unstructured":"Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62:849\u201354.","journal-title":"J Clin Psychiatry."},{"key":"458_CR20","doi-asserted-by":"publisher","first-page":"903","DOI":"10.4088\/JCP.v65n0704","volume":"65","author":"MC Zanarini","year":"2004","unstructured":"Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004;65:903\u20137.","journal-title":"J Clin Psychiatry."},{"key":"458_CR21","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.4088\/JCP.08m04138yel","volume":"72","author":"MC Zanarini","year":"2011","unstructured":"Zanarini MC, Schulz SC, Detke HC. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2011;72:1353\u201362. doi:10.4088\/JCP.v65n0704.","journal-title":"J Clin Psychiatry."},{"key":"458_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00003495-200161010-00011","volume":"61","author":"N Bhana","year":"2001","unstructured":"Bhana N, Foster RH, Olney R. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61:111\u201361. doi:10.2165\/00003495-200161010-00011.","journal-title":"Drugs."},{"key":"458_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1192\/bjp.bp.107.037903","volume":"193","author":"SC Schulz","year":"2008","unstructured":"Schulz SC, Zanarini MC, Bateman A. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008;193:485\u201392. doi:10.1192\/bjp.bp.107.037903.","journal-title":"Br J Psychiatry."},{"key":"458_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00213-008-1456-5","volume":"204","author":"O Franberg","year":"2009","unstructured":"Franberg O, Marcus MM, Ivanov V, Schilstrom B, Shahid M, Svensson TH. Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology. 2009;204:251\u201364. doi:10.1007\/s00213-008-1456-5.","journal-title":"Psychopharmacology."},{"key":"458_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/JCP.0b013e3181d35d6b","volume":"30","author":"JM Kane","year":"2010","unstructured":"Kane JM, Cohen M, Zhao J. Efficacy and safety of asenapine in a placebo-and haloperiodol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30:106\u201315. doi:10.1097\/JCP.0b013e3181d35d6b.","journal-title":"J Clin Psychopharmacol."},{"key":"458_CR26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.4088\/JCP.10m06306","volume":"72","author":"JM Kane","year":"2011","unstructured":"Kane JM, Mackle M, Snow-Adami L. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry. 2011;72:349\u201355. doi:10.4088\/JCP.10m06306.","journal-title":"J Clin Psychiatry."},{"key":"458_CR27","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","volume":"68","author":"SG Potkin","year":"2007","unstructured":"Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007;68:1492\u2013500. doi:10.4088\/JCP.v68n1004.","journal-title":"J Clin Psychiatry."},{"key":"458_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/JCP.0b013e31823f880a","volume":"32","author":"RW Buchanan","year":"2012","unstructured":"Buchanan RW, Panagides J, Zhao J. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012;32:36\u201345. doi:10.1097\/JCP.0b013e31823f880a.","journal-title":"J Clin Psychopharmacol."},{"key":"458_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1055\/s-0030-1248313","volume":"43","author":"J Schoemaker","year":"2010","unstructured":"Schoemaker J, Naber D, Vrijland P. Long-term assessment of asenapine versus olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43:138\u201346. doi:10.1055\/s-0030-1248313.","journal-title":"Pharmacopsychiatry."},{"key":"458_CR30","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1399-5618.2009.00748.x","volume":"11","author":"RS McIntyre","year":"2009","unstructured":"McIntyre RS, Cohen M, Zhao J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disorders. 2009;11:673\u201386. doi:10.1111\/j.1399-5618.2009.00748.x.","journal-title":"Bipolar Disorders."},{"key":"458_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jad.2009.12.028","volume":"122","author":"RS McIntyre","year":"2010","unstructured":"McIntyre RS, Cohen M, Zhao J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010;122:27\u201338. doi:10.1016\/j.jad.2009.12.028.","journal-title":"J Affect Disord."},{"key":"458_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JCP.0b013e31823f872f","volume":"32","author":"A Szegedi","year":"2012","unstructured":"Szegedi A, Calabrese JR, Stet L. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol. 2012;32:46\u201355. doi:10.1097\/JCP.0b013e31823f872f.","journal-title":"J Clin Psychopharmacol."},{"key":"458_CR33","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/YIC.0000000000000004","volume":"29","author":"A Martin-Blanco","year":"2014","unstructured":"Martin-Blanco A, Patrizi B, Villalta L. Asenapine in the treatment of borderline personality disorder: an atypical antipsychotic alternative. Int Clin Psychopharmacol. 2014;29:120\u20133. doi:10.1097\/YIC.0000000000000004.","journal-title":"Int Clin Psychopharmacol."},{"key":"458_CR34","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1176\/ajp.154.4.466","volume":"154","author":"GD Tollefson","year":"1997","unstructured":"Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry. 1997;154:466\u201374. doi:10.1176\/ajp.154.4.466.","journal-title":"Am J Psychiatry."},{"key":"458_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4088\/JCP.v66n0104","volume":"66","author":"RS McIntyre","year":"2005","unstructured":"McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 2005;66:28\u201336.","journal-title":"J Clin Psychiatry."},{"key":"458_CR36","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1517\/14740338.2014.908183","volume":"13","author":"L Citrome","year":"2014","unstructured":"Citrome L. Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opin Drug Saf. 2014;13:803\u201330. doi:10.1517\/14740338.2014.908183.","journal-title":"Expert Opin Drug Saf."},{"key":"458_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4088\/JCP.12m08271","volume":"75","author":"DE Kemp","year":"2014","unstructured":"Kemp DE, Zhao J, Cazarola P. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder. J Clin Psychiatry. 2014;75:238\u201345. doi:10.4088\/JCP.12m08271.","journal-title":"J Clin Psychiatry."},{"key":"458_CR38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/YIC.0b013e32836290d2","volume":"28","author":"A Vita","year":"2013","unstructured":"Vita A, De Peri L, Siracusano A. Efficacy and tolerability of asenapine for acute mania in bipolar I disorder: meta-analyses of randomized-controlled trials. Int Clin Psychopharmacol. 2013;28:219\u201327. doi:10.1097\/YIC.0b013e32836290d2.","journal-title":"Int Clin Psychopharmacol."},{"key":"458_CR39","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Press; 2013.","edition":"5"},{"key":"458_CR40","volume-title":"Structured clinical interview for DSM-IV axis II disorders (SCID-II)","author":"MB First","year":"1997","unstructured":"First MB, Gibbon M, Spitzer RL. Structured clinical interview for DSM-IV axis II disorders (SCID-II). Washington (DC): American Psychiatric Press; 1997."},{"key":"458_CR41","volume-title":"Structured clinical interview for DSM-IV axis I disorders (SCID-I)","author":"MB First","year":"1997","unstructured":"First MB, Spitzer RL, Gibbon M. Structured clinical interview for DSM-IV axis I disorders (SCID-I). Washington (DC): American Psychiatric Press; 1997."},{"key":"458_CR42","unstructured":"Guy W. Clinical global impression (C.G.I.). Ecdeu assessment manual for psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1967, pp. 218\u2013222."},{"key":"458_CR43","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56\u201362. doi:10.1136\/jnnp.23.1.56.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"458_CR44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50\u20135. doi:10.1111\/j.2044-8341.1959.tb00467.x.","journal-title":"Br J Med Psychol."},{"key":"458_CR45","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1176\/ajp.149.8.1119-a","volume":"149","author":"HH Goldman","year":"1992","unstructured":"Goldman HH, Skodol AE, Lave TR. Revising Axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry. 1992;149:1148\u201356. doi:10.1176\/ajp.149.9.1148.","journal-title":"Am J Psychiatry."},{"key":"458_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1521\/pedi.17.1.45.24053","volume":"17","author":"A Arntz","year":"2003","unstructured":"Arntz A, Van den Hoorn M, Cornelis J. Reliability and validity of the Borderline Personality Disorder Severity Index. J Pers Disord. 2003;17:45\u201359. doi:10.1521\/pedi.17.1.45.24053.","journal-title":"J Pers Disord"},{"key":"458_CR47","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2466\/pr0.1965.16.2.547","volume":"16","author":"ES Barratt","year":"1965","unstructured":"Barratt ES. Factor analysis of some psychometric measures of impulsiveness and anxiety. Psychol Rep. 1965;16:547\u201354. doi:10.2466\/pr0.1965.16.2.547.","journal-title":"Psychol Rep."},{"key":"458_CR48","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/00005053-198809000-00007","volume":"176","author":"SR Kay","year":"1988","unstructured":"Kay SR, Wolkenfelf F, Murrill LM. Profiles of aggression among psychiatric patients: I. Nature and prevalence. J Nervous Mental Dis. 1988;176:539\u201346. doi:10.1097\/00005053-198809000-00007.","journal-title":"J Nervous Mental Dis."},{"key":"458_CR49","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/(SICI)1097-4679(199811)54:7<973::AID-JCLP11>3.0.CO;2-H","volume":"54","author":"RA Sansone","year":"1998","unstructured":"Sansone RA, Wiederman MW, Sansone LA. The Self-harm Inventory (SHI): development of a scale for identifying self-destructive behaviors and borderline personality disorder. J Clin Psychol. 1998;54:973\u201383.","journal-title":"J Clin Psychol."},{"key":"458_CR50","unstructured":"Guy W. Dosage Record and Treatment Emergent Symptoms scale (DOTES). ECDEU Assessment Manual for Psychopharmacology\u2014Revised. DHEW Publication No. ADM 76-338. NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Alcohol, Drug Abuse, and Mental Health Administration, Public Health Service, US Department of Health, Education, and Welfare, Rockville, MD, 1976; pp. 223\u2013244."},{"key":"458_CR51","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.4088\/JCP.11r07596","volume":"73","author":"A Szegedi","year":"2012","unstructured":"Szegedi A, Verweij P, van Duijnhoven W. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics. J Clin Psychiatry. 2012;73:1533\u201340. doi:10.4088\/JCP.11r07596.","journal-title":"J Clin Psychiatry."},{"key":"458_CR52","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1186\/1471-244X-11-101","volume":"11","author":"A Szegedi","year":"2011","unstructured":"Szegedi A, Zhao J, van Willingenburg A. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry. 2011;11:1186\u2013471. doi:10.1186\/1471-244X-11-101.","journal-title":"BMC Psychiatry."},{"issue":"1","key":"458_CR53","first-page":"27","volume":"47","author":"JS Amon","year":"2017","unstructured":"Amon JS, Johnson SB, El-Mallakh RS. Asenapine for the control of physical aggression: a prospective naturalist pilot study. Psychopharmacol Bull. 2017;47(1):27\u201332.","journal-title":"Psychopharmacol Bull."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-017-0458-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0458-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0458-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:50:54Z","timestamp":1628617854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-017-0458-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,24]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["458"],"URL":"https:\/\/doi.org\/10.1007\/s40263-017-0458-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,24]]},"assertion":[{"value":"24 July 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This research received no sources of funding to assist with conducting the study and preparing the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The four authors, Paola Bozzatello, Paola Rocca, Maria Uscinska, and Silvio Bellino, declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Each patient participated voluntarily in the study after providing written informed consent. Declaration of Helsinki guidelines (1964) were followed. Ethical approval was obtained from the ethics committee of University Hospital \u201cCitt\u00e0 della Salute e della Scienza \u2013 Ospedale dell\u2019Ordine Mauriziano\u201d of Turin.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent and ethics approval"}}]}}